Oxford Vacmedix Uk Limited
Biotechnology Research • 
Oxford, England, United Kingdom • 1-10 Employees
Company overview
| Headquarters | The Magdalen Centre, Oxford Science Park, Oxford, England OX4 4GA, GB |
| Phone number | +441865784074 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2012 |
| Employees | 1-10 |
| Socials |
Key Contacts at Oxford Vacmedix Uk Limited
Sang Tae Park
Member Board Of Directors
William Finch
Ceo
Shisong Jiang
Director
About Oxford Vacmedix Uk Limited
Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases. The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases. OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents. OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China in 2018. The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.
Oxford Vacmedix Uk Limited revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | $12,500,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Oxford Vacmedix Uk Limited has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Explore Oxford Vacmedix Uk Limited's funding history, including investment rounds, total capital raised, and key backers.
Oxford Vacmedix Uk Limited Tech Stack
Discover the technologies and tools that power Oxford Vacmedix Uk Limited's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
JavaScript libraries
Maps
Page builders
JavaScript libraries
Analytics
Web servers
JavaScript libraries
Programming languages
Blogs
Spain
Japan
Sweden
Frequently asked questions
4.8
40,000 users
